Leave No-One Behind: A Retrospective Study of Hepatitis C Testing and Linkage to Care for Hospital Inpatients
Open Access
- 31 March 2023
- Vol. 15 (4), 913
- https://doi.org/10.3390/v15040913
Abstract
Hospital admissions are a missed opportunity to engage people living with hepatitis C virus (HCV) into care. This study aimed to describe the proportion of hospital inpatients and emergency department (ED) patients identified with hepatitis C who were subsequently linked to care and treatment at a metropolitan health service in Melbourne, Australia. Data were collected retrospectively from hospital databases (admissions, notifiable diseases, and pharmacy) for all adults admitted or attending the ED with separation coding indicating hepatitis C infection from March 2016 to March 2019. There were 2149 patients with at least one separation with hepatitis C coding. 15.4% (331/2149) had a documented antibody test, 4.6% (99/2149) had a documented RNA test, and 8.3% (179/2149) had a DAA prescription dispensed by hospital pharmacy. Antibody positivity was 95.2% (315/331) and RNA (when completed) was detected in 37.4% (37/99). Hepatitis specialist units had the highest rate of hepatitis C coded separations and RNA testing (39/88; 44.3%), mental health had the highest rate of antibody testing (70/276; 25.4%). Emergency had the lowest rate of antibody testing (101/1075; 13.7%) and the third highest rate of RNA testing (32/94; 34.1%), but the highest rate of RNA detected (15/32; 46.9%). This study highlights key steps to improve the care cascade. Simplified diagnostic pathways, expansion of hepatitis C care services, and clear in-hospital pathways to link patients to care would be beneficial in this setting. To scale up hepatitis C testing and treatment as part of national elimination strategies, hospital systems need to target interventions to their local data.Keywords
This publication has 19 references indexed in Scilit:
- Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapyJHEP Reports, 2021
- Hepatitis C treatment in a co‐located mental health and alcohol and drug service using a nurse‐led model of careJournal of Viral Hepatitis, 2021
- Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency departmentInternational Journal of Drug Policy, 2019
- Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject DrugsClinical Infectious Diseases, 2019
- Treatment access is only the first step to hepatitis C elimination: experience of universal anti‐viral treatment access in AustraliaAlimentary Pharmacology & Therapeutics, 2019
- Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: A prospective cohort studyInternational Journal of Drug Policy, 2019
- Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in AustraliaApplied Health Economics and Health Policy, 2018
- Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct‐acting antiviral therapy for hepatitis CJournal of Viral Hepatitis, 2018
- Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access2018
- Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascadeInternational Journal of Drug Policy, 2017